Acadia (ACAD) | Financial Analysis & Statements
Acadia Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
284.0M
Gross Profit
257.8M
90.77%
Operating Income
17.4M
6.12%
Net Income
273.6M
96.33%
EPS (Diluted)
$1.60
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
336.8M
Shareholders Equity
1.2B
Debt to Equity
0.27
Cash Flow Metrics
Operating Cash Flow
268.9M
Free Cash Flow
46.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Acadia Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 957.8M | 726.4M | 517.2M | 484.1M |
| Cost of Goods Sold | 89.0M | 81.8M | 41.6M | 10.2M | 19.1M |
| Gross Profit | 982.5M | 876.0M | 684.8M | 507.1M | 465.0M |
| Gross Margin % | 91.7% | 91.5% | 94.3% | 98.0% | 96.0% |
| Operating Expenses | |||||
| Research & Development | 328.8M | 303.2M | 351.6M | 361.6M | 239.4M |
| Selling, General & Administrative | 548.9M | 488.4M | 406.6M | 369.1M | 396.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 877.7M | 791.7M | 758.2M | 730.7M | 635.4M |
| Operating Income | 104.8M | 84.3M | -73.4M | -223.6M | -170.4M |
| Operating Margin % | 9.8% | 8.8% | -10.1% | -43.2% | -35.2% |
| Non-Operating Items | |||||
| Interest Income | 31.7M | 25.5M | 17.2M | 6.6M | 591.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 2.4M | 148.3M | 5.1M | 3.5M | 2.3M |
| Pre-tax Income | 138.9M | 258.1M | -51.0M | -213.4M | -167.5M |
| Income Tax | -252.1M | 31.6M | 10.2M | 2.5M | 351.0K |
| Effective Tax Rate % | -181.5% | 12.3% | 0.0% | 0.0% | 0.0% |
| Net Income | 391.0M | 226.5M | -61.3M | -216.0M | -167.9M |
| Net Margin % | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% |
| Key Metrics | |||||
| EBITDA | 116.6M | -46.4M | -67.8M | -221.6M | -167.1M |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Basic Shares Outstanding | 168356000 | 165717000 | 163819000 | 161683000 | 160493000 |
| Diluted Shares Outstanding | 168356000 | 165717000 | 163819000 | 161683000 | 160493000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Acadia Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 177.7M | 319.6M | 188.7M | 114.8M | 147.4M |
| Short-term Investments | 642.0M | 436.4M | 250.2M | 302.0M | 373.3M |
| Accounts Receivable | 121.5M | 98.7M | 98.3M | 62.2M | 64.4M |
| Inventory | 34.7M | 21.9M | 35.8M | 6.6M | 7.9M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 1.1B | 938.3M | 616.1M | 507.9M | 617.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 47.4M | 46.6M | 51.9M | 55.6M | 58.3M |
| Goodwill | 108.9M | 119.8M | 65.5M | 0 | 0 |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 338.3M | 78.9M | 10.9M | 18.3M | 16.0M |
| Total Non-Current Assets | 502.1M | 249.4M | 132.8M | 79.9M | 82.3M |
| Total Assets | 1.6B | 1.2B | 749.0M | 587.8M | 700.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.9M | 16.2M | 17.5M | 12.7M | 6.9M |
| Short-term Debt | 11.6M | 10.0M | 9.4M | 9.3M | 8.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 277.1M | 394.9M | 254.3M | 125.6M | 96.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 40.6M | 42.0M | 47.8M | 52.7M | 56.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 19.1M | 18.1M | 15.1M | 9.1M | 7.0M |
| Total Non-Current Liabilities | 59.7M | 60.1M | 62.9M | 61.8M | 63.2M |
| Total Liabilities | 336.8M | 455.0M | 317.2M | 187.4M | 159.2M |
| Equity | |||||
| Common Stock | 16.0K | 16.0K | 16.0K | 16.0K | 16.0K |
| Retained Earnings | -1.8B | -2.2B | -2.4B | -2.4B | -2.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 732.8M | 431.8M | 400.4M | 540.9M |
| Key Metrics | |||||
| Total Debt | 52.2M | 52.0M | 57.2M | 62.0M | 64.4M |
| Working Capital | 785.0M | 543.4M | 361.9M | 382.3M | 521.8M |
Balance Sheet Composition
Acadia Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 391.0M | 226.5M | -61.3M | -216.0M | -167.9M |
| Depreciation & Amortization | 11.8M | 15.9M | 5.6M | 2.0M | 3.3M |
| Stock-Based Compensation | 52.1M | 67.0M | 66.4M | 68.2M | 63.6M |
| Working Capital Changes | -66.6M | -50.3M | -57.3M | 11.2M | -18.2M |
| Operating Cash Flow | 138.4M | 259.1M | -46.7M | -134.6M | -119.1M |
| Investing Activities | |||||
| Capital Expenditures | -4.7M | -523.0K | -50.0K | 0 | -1.1M |
| Acquisitions | -98.8M | - | - | - | - |
| Investment Purchases | -692.6M | -505.1M | -370.0M | -363.2M | -492.8M |
| Investment Sales | 493.5M | 328.6M | 442.0M | 436.4M | 422.8M |
| Investing Cash Flow | -302.6M | -30.5M | 72.0M | 73.2M | -71.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 49.9M | 6.8M | 25.1M | 8.2M | 18.2M |
| Free Cash Flow | 105.1M | 157.2M | -23.3M | -114.0M | -126.8M |
| Net Change in Cash | -114.3M | 235.4M | 50.5M | -53.1M | -172.0M |
Cash Flow Trend
Acadia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
9.61
Forward P/E
24.13
Price to Book
3.07
Price to Sales
3.52
PEG Ratio
0.11
Profitability Ratios
Profit Margin
36.49%
Operating Margin
6.12%
Return on Equity
39.89%
Return on Assets
4.76%
Financial Health
Current Ratio
3.83
Debt to Equity
4.25
Beta
0.83
Per Share Data
EPS (TTM)
$2.30
Book Value per Share
$7.21
Revenue per Share
$6.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ACAD | 3.7B | 9.61 | 3.07 | 39.89% | 36.49% | 4.25 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






